Raymond James Financial
SVA

Raymond James Financial’s Sinovac Biotech, Ltd SVA Stock Holding History

Raymond James Financial’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,511
Closed – – 7034
2025
Q2 		$0 Buy
+2,511
New – ﹤0.01% 7078

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

Raymond James Financial's SVA Position: Q3 2025 in Review

Raymond James Financial sold out of Sinovac Biotech, Ltd (SVA) in Q3 2025, closing a stake of 2,511 shares.

Raymond James Financial first reported a position in SVA in Q2 2025 and held it in 1 quarter. The position peaked at $0 in Q2 2025. 27 funds tracked by Wall St. Rank hold SVA as of Q3 2025.

  • Raymond James Financial reported no remaining Sinovac Biotech, Ltd position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,511 Sinovac Biotech, Ltd shares in Q3 2025.
  • Raymond James Financial first reported a position in Sinovac Biotech, Ltd in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Sinovac Biotech, Ltd position peaked at $0 in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.